Determination of influenza B identity and potency in quadrivalent inactivated influenza vaccines using lineage-specific monoclonal antibodies.
Co-circulation of two antigenically and genetically distinct lineages of influenza B virus, represented by prototype viruses B/Victoria/2/1987 and B/Yamagata/16/1988, has led to the development of quadrivalent influenza vaccines that contain two influenza B antigens. The inclusion of two influenza B...
Main Authors: | Swati Verma, Jackeline Soto, Anupama Vasudevan, Falko Schmeisser, Esmeralda Alvarado-Facundo, Wei Wang, Carol D Weiss, Jerry P Weir |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5396888?pdf=render |
Similar Items
-
Antibodies to antigenic site A of influenza H7 hemagglutinin provide protection against H7N9 challenge.
by: Falko Schmeisser, et al.
Published: (2015-01-01) -
Quadrivalent inactivated influenza vaccine (VaxigripTetra™)
by: Viviane Gresset-Bourgeois, et al.
Published: (2018-01-01) -
Review of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines
by: Edward W. Thommes, et al.
Published: (2017-04-01) -
Evaluation of determinants of the serological response to the quadrivalent split‐inactivated influenza vaccine
by: Shaohuan Wu, et al.
Published: (2022-05-01) -
Development of the quadrivalent live attenuated influenza vaccine including two influenza B lineages – Victoria and Yamagata
by: Yu. A. Desheva, et al.
Published: (2016-02-01)